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Abstract
The 4th international melanoma congress of the
Society for Melanoma Research (SMR), organized
by Marianne Berwick (University of New Mexico),
Paul Chapman (Memorial Sloan-Kettering Cancer
Center), Rene Gonzalez (University of Colorado) and
Ze’ev Ronai (Burnham Institute), was held at the
Marriott Hotel in downtown New York on Novem-
ber 2007. The congress was attended by a record
high number of attendees (over 500 delegates) who
joined to discuss recent advances in melanoma biol-
ogy and therapy. About 40% of the participants
arrived from 39 countries, a testament to the high
impact of this annual gathering on the international
melanoma community. Over 120 of the participants
were students or postdoctoral fellows, representing
a most impressive fraction of young scientists
engaged in melanoma research. The meeting con-
sisted of more than 50 plenary and minisymposia
presentations, stimulating the exchange of unpub-
lished data and novel ideas, and helping to forge
new collaborations that are anticipated to facilitate
significant advances in basic, translational and clini-
cal melanoma research. Another major focus of this
meeting was over 160 posters, which were heavily
attended and provided an effective forum for exten-
sive informal discussions. This report will highlight
the major scientific themes and advances of this
most successful meeting, and provide a useful per-
spective on the current state of melanoma research,
as well as where the field should be heading.
doi: 10.1111/j.1755-148X.2007.00437.x
Day 1 ⁄ Keynote Address. Speaker: Boris Bastian
Dr. Bastian (University of California at San Francisco,
San Francisco, CA) was selected as the keynote
speaker for this congress based on his seminal contribu-
tion to the melanoma field over the past decade, with
important findings highlighting the genetic differences
between melanoma subtypes. In his presentation
Dr. Bastian showed that melanomas with BRAF muta-
tions differed in their histomorphology from melanomas
without such mutations, a finding that could be used to
improve the current classification of melanoma to incor-
porate therapeutically relevant genetic findings. As a fol-
low-up to his prior discovery that KIT is mutant and ⁄ or
amplified in certain melanoma types, he presented a
patient with metastatic mucosal melanoma and a KIT
mutation, who showed a major clinical response to
imatinib. Dr. Bastian also presented a discovery made in
collaboration with Catherine van Raamsdonk and Greg
Barsh, that oncogenic mutations in GNAQ are found in
over 80% of blue nevi and about 50% of uveal melano-
mas. GNAQ is a G-protein of the alpha-q family that acts
downstream of G-protein coupled receptors. Expression
of the mutant protein in immortalized melanocytes was
sufficient to induce the transformed phenotypes, with
an efficiency comparable to mutant NRAS. GNAQ muta-
tions led to activation of the MAP-kinase pathway and
the observation that mutations are mutually exclusive
with KIT, BRAF and NRAS indicate that mutant GNAQ
may have partially overlapping roles in melanocyte trans-
formation. Dr. Bastian also presented the development
of a FISH assay designed to detect chromosomal aber-
rations in melanocytic tumors. This test was developed
based on his group’s finding of different patterns ofAddress correspondence to G. Merlino,
e-mail: gmerlino@helix.nih.gov
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chromosomal aberrations between melanoma and nevi.
According to Dr. Bastian, the test was designed
to improve diagnostic accuracy in melanocytic neopla-
sms that cannot be unequivocally categorized by current
methods. The test will be distributed by Abbott
Molecular.
Day 1 ⁄ Session 1. Why melanocytes develop into
melanoma (early stages in melanoma
development). Chair: Dorothy Bennett
Nearly a decade ago, melanoma was considered a
genetic black box. We still lack molecular markers for
tumor progression, and the molecular basis underlying
the persistent resistance of metastatic melanomas to
current anticancer modalities requires better definition.
However, we no longer walk in the dark. Comprehen-
sive cytogenetic, mutational and functional analyses in
melanoma specimens and cell lines are revealing a com-
plex network of changes in gene expression. Dr. Ben-
nett (St. George’s, University of London, UK) reviewed
some of what now are considered to be melanoma hall-
marks, which appear to develop in a spatio ⁄ temporal
sequence. A classical example is the BRAF>NRAS>ERK
pathway, which is targeted by mutations in early benign
melanocytic lesions (nevi). Dysplastic nevi and subse-
quently primary melanomas with radial or vertical
growth patterns (RGP, VGP, respectively) acquire
changes in tumor suppressive mechanisms involving
p16INK4a ⁄ Rb or b-catenin, among others. VGP and met-
astatic melanomas invariably present with a variety of
additional defects in mechanisms of tumor control,
including programs of apoptosis and cellular senes-
cence. Thus, in vivo, nevus cells are mitotically inactive
and show classical markers of premature senescence,
including the so-called acidic senescence-associated
b-galactosidase activity, SA-b-Gal. Melanoma cells, par-
ticularly in the VGP and metastatic phases, re-activate
telomerase function and acquire additional defects in
senescence mediators. Still, it is unclear if nevus cells
or cells from in situ or non-invasive melanomas (i.e.,
RGP cells) can be reactivated by appropriate stimuli. To
address this question, Dr. Bennett and collaborators
biopsied common and dysplastic nevi, as well as RGP
and VGP tumors, and determined their clonogenic
potential under culture conditions. As expected, nearly
all explants from nevi either died or arrested their prolif-
eration after a short-term culture. However, there were
exceptions, particularly for dysplastic cases, suggesting
that not all cells in nevi are necessarily committed to an
irreversible senescent-like state. Proliferative cells could
also be isolated from RGP tumors; however, most of
these cells were highly unstable in culture, and would
senesce or collapse via mitotic catastrophe. These
results emphasize the dynamic nature of pigmented
lesions, and the fact that tumor suppressive mecha-
nisms acting at early stages of melanoma genesis are
potent, but not infallible.
Shin-Ichi Nishikawa (RIKEN, Kobe, Japan) addressed
the theme of proliferation, quiescence and differentia-
tion in melanocyte stem cells. Dr. Nishikawa exploited
the fact that in mice, at least in mature hair follicles,
melanocytes and their progeny (i.e., the differentiated
melanocytes) are distributed in geographically distinct
compartments. Melanocyte stem cells, present in the
bulge region, are maintained in a quiescent state until
the hair regeneration cycle is initiated. Proliferating and
differentiating melanocytes are located at the bottom of
the hair follicle (bulb). The Nishikawa laboratory isolated
single cells from the bulge or the hair bulb using as
source hair from mice they had previously engineered
to express green fluorescent protein (GFP) in the melan-
ocytic compartment (thus allowing for cell sorting).
Next, they performed single cell-based cDNA arrays of
these different melanocytic populations. A molecular
signature for quiescent melanocyte stem cells was
found to involve: (i) commitment to quiescence, in part
involving NOTCH signaling; (ii) global suppression of
housekeeping gene expression associated with RNA
polymerase II inhibition; (iii) suppression of Wnt signal-
ing; and (iv) acquisition of a cell autonomous ability to
survive in a ‘‘niche-independent manner’’ in the absence
of survival mediators such as KIT. Further analyses with
proliferating melanocytes are now possible through
co-culture with XB2, an immortalized keratinocyte cell
line, and specific combinations of SCF and bFGF defined
by the Nishikawa group. The question still remains as to
how distant or related mouse and human skin compart-
ments are, but this study by Dr. Nishikawa suggests
the existence of previously unexplored pathways that
may modulate the fate of melanocytic stem cells.
In addition to increased proliferation and blocked dif-
ferentiation programs, melanomas are notorious for
their invasive potential. Since in the human adult skin,
mature melanocytes are tightly restricted to the basal
layer of the epidermis, it is reasonable to hypothesize
that early stages of melanoma development involve the
deactivation of potent suppressive mechanism(s) to
escape from the control of epidermal keratinocytes.
Gavin Robertson (Penn State University, Hershey, PA)
presented data showing that the short arm of the chro-
mosome 10 contains one such activity. The starting
point of this work was the long known observation that
chromosome 10 is frequently lost during melanoma pro-
gression. There are well known tumor suppressors iden-
tified on the long arm of this chromosome (e.g., PTEN),
but not on short arm. The Robertson group used micro-
cell fusion to generate cell hybrids to transfer segments
of chromosome 10 from a positive donor cell to defi-
cient melanoma cells. Among the hybrid melanoma cells
generated, those containing 10p15 were found to have
a reduced proliferative capacity when placed in type I
collagen. Moreover, xenografts of these cells were
significantly less tumorigenic and showed a signifi-
cantly disorganized ECM (extracellular matix). Genetic
Fisher et al.
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and functional mapping narrowed the set of candidate
genes mapping at 10p15 to KLF6 (Krüppel like factor 6),
a gene previously described to control various tumor-
associated proteins, including p21, TGF-b and E-cadherin.
Dr. Robertson showed a progressive loss in expression
of KLF6 in RGP and VGP melanoma tumors, and a high
frequency of inactivation in metastatic melanoma speci-
mens. By restoring KLF6 levels in deficient melanoma
cell lines, Dr. Robertson showed that this protein can
restrict activating mutations in the MAPK pathway and
modulate survival of melanoma cells that cross the
basement membrane and start interacting with, and
reorganizing, dermal collagen. These results point to
KLF6 as a new tumor suppressor in melanoma.
Scott Lowe (Cold Spring Harbor Laboratory, Cold
Spring Harbor, NY) presented compelling data that
emphasized the power of retroviral-mediated gene
transfer to generate mosaic models of cancer in mice.
Dr. Lowe presented examples of elegant reconstitution
systems where stem cells of hematopoietic or liver nat-
ure (to generate specific types of leukemia or hepatocel-
lular carcinoma, respectively) can be transduced by
retroviral-mediated gene transfer with candidate onco-
genes or tumor suppressors. The retroviruses used can
also encode GFP, permitting the sorting of positive cells
and fluorescence-based imaging in vivo. Genetically
engineered progenitor cells are transferred to lethally
irradiated mice to repopulate stem cell compartments.
Using this approach the Lowe group have identified syn-
ergistic interactions between Myc and Bcl-2, p53 or
AKT, among others. Dr. Lowe also presented recent
work from his group further defining the role of down-
stream effectors in the mTOR pathway, specifically
eIF4E, MNK1 ⁄ 2 or TSC-2 in the development of Myc-
driven B-cell lymphomas. Retroviral-mediated gene
transfer can also be used to inactivate genes, for exam-
ple, by transducing short interfering RNAs, or engi-
neered to be activated or inactivated in a conditional
manner (e.g., with tetracycline responsive elements).
This strategy can be performed for single genes, or in a
high throughput manner, using proprietary or commer-
cial shRNA libraries. A key role of Rho-GAP protein
(DLC1) was identified in this manner in models of hepa-
tocellular carcinoma. Skin progenitor cells may not be as
amenable for whole-body reconstitution assays as
hematopoietic or fetal liver precursor cells, but there is
still the exciting possibility of genetic engineering artifi-
cial human skin for long-term grafting experiments in
recipient mice.
Day 1 ⁄ Session 2. Why melanomas are so metastatic
(late stages in melanoma development).
Chair: Menashe Bar-Eli
Dr. Bar-Eli (MD Anderson Cancer Center, Houston, TX)
opened the session by discussing the use of tissue
arrays containing nevi, primary and metastatic mela-
noma for the identification of novel prognostic markers
in melanoma progression. He showed that nuclear-dis-
tributed Activator Protein-2a (AP-2) was high in normal
melanocytes and melanocytic nevi and decreased in
melanomas in a disease progression manner. In addi-
tion, expression of nuclear AP-2 and expression of the
Protease-Activated Receptor-1 (PAR-1) protein are inver-
sely correlated during melanoma progression. Dr. Bar-Eli
also discussed the tumor promoter activity of platelet
activating factor (PAF-1). PAF-1, which is produced in
large amounts by the tumor microenvironment, facili-
tates phosphorylation of the transcription factors CREB
and ATF-1, which in turn regulate TGF-a, Bcl2 and other
genes involved in melanoma metastasis.
J. William Harbour (Washington School of Medicine,
St. Louis, MO) discussed the particular biology of uveal
melanomas. These tumors, which are mostly homoge-
neous, can be classified into two groups. Class1 uveal
tumors display mostly a melanocytic morphology,
express melanocytic markers and are associated with
greater than 95% survival. In contrast, Class2 tumors,
which are associated with less than 25% survival, show
significant down-regulation of neural crest and melano-
cytic genes including DCT, SILV and TYR. Class2
tumors display an epithelioid morphology, localization of
E-cadherin and b-catenin to the plasma membrane, up-
regulation of SPARC and chromosomal alterations. In
particular, monosomy of chromosome 3 was found to
be significantly associated with metastasis to the liver.
Dr. Harbor also reported that Id2, a b-catenin target, is
involved in the switch between Class1 and Class2
tumors.
Michael Detmar (ETH Zurich, Switzerland) presented
data that melanomas can actively induce the formation
of lymphatic vessels, which promotes lymph node
metastasis. His recent studies demonstrated that the
degree of melanoma lymphangiogenesis can serve as a
novel predictor of lymph node metastasis and overall
patient survival, and that the extent of lymphatic vessel
growth in primary human cutaneous melanomas was
the most sensitive parameter for predicting whether
these tumors had already metastasized to the sentinel
lymph node at the time of surgery. Recently, his group
showed - for the first time - that metastastic tumor cells
can induce lymphangiogenesis within sentinel lymph
nodes, furthering their metastatic spread. Surprisingly,
tumor cells induced lymph node lymphangiogenesis
already before they metastasized, giving a new twist to
the seed-and-soil hypothesis and suggesting that
tumors can prepare lymph nodes for their future arrival.
This new concept indicates that lymph node lymphan-
giogenesis represents a novel target for inhibiting
and ⁄ or imaging melanoma metastasis. Using laser cap-
ture microdissection (LCM) and transcriptional profiling
of tumor-associated lymphatic vessels, several new acti-
vation markers of these vessels were identified.
Don Nguyen (Memorial Sloan-Kettering Cancer
Center, New York, NY) described a functional approach
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for the selection of metastatic cells in vivo, in which he
has identified different gene sets that mediate the tis-
sue specific dissemination of cells originally obtained
from advanced adenocarcinomas (breast and lung),
either as established cell lines or fresh patient pleural
effusions. In the context of breast cancer metastasis to
the lung, Dr. Nguyen has derived a lung metastasis sig-
nature (LMS) that is differentially expressed in a subset
of primary tumors from patients that are likely to suffer
pulmonary relapse. This clinical validation demonstrates
that certain metastatic traits may be already selected in
a subset of aggressive primary tumors. Using genetic
and pharmacological approaches, Dr. Nguyen showed
that the EGF receptor ligand epiregulin, the cyclooxy-
genase COX-2, and the matrix metalloproteinases 1 and
2 expressed in breast cancer cells collectively facilitate
the assembly of new tumor blood vessels, the release
of tumor cells into the circulation, and the breaching of
lung capillaries by circulating tumor cells to seed pulmo-
nary metastases. These insights reveal how aggressive
primary tumorigenic functions can be mechanistically
coupled to greater lung metastatic potential, and how
such functions may be therapeutically targeted.
Day 1 ⁄ Session 3. Why melanomas don’t die.
Chair: Estela Medrano
Dr. Medrano (Baylor College of Medicine, Houston, TX)
opened the session by discussing how chromatin
remodeling affects cellular senescence in melanocytic
nevi and apoptosis in melanoma. Benign melanocytic
nevi are a classical example of oncogene-induced senes-
cence, regulated by the p16INK4a ⁄ RB pathway. How-
ever, it is unclear what prevents the reversal of
senescence since these lesions display a prominent
mosaicism in p16INK4a expression. Dr. Medrano
reported that histone deacetylase 1 (HDAC1) is required
for chromatin remodeling events leading to heterochro-
matization and maintenance of the senescence state in
nevi and melanocytes, localizing to nuclear foci with RB,
SUV39H1 and HP1b. Moreover, overexpression of
HDAC1 induced senescence in p16INK4a-deficient mel-
anoma cells. Her data suggest that melanoma regres-
sion is achievable by therapies aimed at reactivation of
the senescence response. Finally, Dr. Medrano used
human melanoma xenografts to demonstrate how SKI,
in complexes with HDAC1, curtails the growth inhibitory
activity and stimulates the tumor promoting function of
TGF-b. SKI appears to be critical for melanoma viability
as its deficiency prevented melanoma xenograft growth
by reactivation of apoptotic pathways.
David Fisher (Dana-Farber Cancer Institute, Boston,
MA) presented data on the transcription factor MITF,
which plays a fundamental role in melanocyte develop-
ment, pigmentation, and proliferation ⁄ survival. Numer-
ous components of the pigmentation machinery are
direct transcriptional targets of MITF, suggesting that it
is a central mediator of the pigmentary response. MITF
is also a key target of the MSH signaling pathway. Poly-
morphisms in the MSH receptor, MC1R, are associated
with altered pigmentation, and with non-signaling vari-
ants producing the redhair ⁄ fairskinned phenotype.
Dr. Fisher reviewed evidence that a mouse red-
head ⁄ fairskinned model (with features of humanized
skin) was exquisitely UV sensitive and unable to
undergo UV induced pigmentation (tanning). However,
topical application of the cAMP agonist forskolin induced
significant darkening, which was associated with rela-
tive protection against UV-induced skin carcinogenesis.
Dr. Fisher also presented a new methodology based
upon ChIP-chip and nucleosome positioning microarrays,
designed to systematically identify global genomic tran-
scriptional targets of MITF. The approach identifies
MITF occupied locations, and overlays this information
with nucleosome positioning, to provide chromatin
structural data that inform the likely functional impor-
tance of MITF at specific locations. Finally, Dr. Fisher
presented early clinical data on use of the kinase inhibi-
tor Imatinib in patients with mucosal or acral melanoma.
In the study, led by Dr. F. Stephen Hodi, the first KIT
mutated melanoma patient to receive imatinib under-
went a dramatic clinical and radiographic response at all
sites of disease (local and metastatic) within a short
time of treatment initiation. Although only a single
patient was thus far presented, the striking response
suggests that melanoma is indeed vulnerable to onco-
gene addiction-based therapeutic strategies.
Amato Giaccia (Stanford University, Stanford, CA) dis-
cussed the role of bone marrow derived cells (BMDC)
in creating a permissive niche for metastatic cell
growth. He described the role of Lysyl Oxidase (LOX), a
secreted ECM protein involved in cross-linking of colla-
gen and elastin, in tumor cell adhesion and invasive-
ness. LOX is regulated by HIF1, thought to play an
important role in the adaptability of tumor cells to a hyp-
oxic microenvironment and to promote tumor cell inva-
sion and metastasis. Dr. Giaccia described the use of
orthotopic tumor transplants, conditioned media and
purified proteins to show that hypoxia ⁄ HIF1a-induced
LOX is critical to BMDC recruitment and pre-metastatic
niche formation in the host organism. His data suggest
that LOX may represent an attractive therapeutic target
for the treatment and prevention of metastatic disease.
Dr. Giaccia also presented data that the prolyl hydrox-
lase domain protein PHD2 may have tumor suppressor
activity, inhibiting tumor growth in a HIF-independent
manner; PHD2 may regulate expression of the angio-
genic factors Angiogenin and IL-8.
Pablo Lopez Bergami (Burnham Institute, La Jolla, CA)
discussed his evidence identifying c-Jun as a critical tar-
get of ERK pathway. Constitutively active ERK was
shown to increase c-Jun transcription and stability,
which are mediated by CREB and GSK3, respectively.
The subsequent upregulation of c-Jun increases
transcription of target genes, including RACK1 and
Fisher et al.
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PDK1, which in turn positively modulate activation of
the PKC, JNK and Akt pathways, suggesting an impor-
tant role for c-Jun in melanoma.
Barbara Bedogni (Stanford University, Stanford, CA)
discussed her work on the interactive roles of Akt and
Notch1. The active fragment of the Notch1 receptor
(Notch1 intracellular domain, or NIC) can have oncogenic
activity, and constitutive activation of Notch1 is prefer-
entially expressed in some human melanomas. More-
over, Akt-dependent tumors express high levels of
nuclear Notch1-NIC. Notch1 activation is associated with
activation of the PI(3)K ⁄ Akt pathway in melanoma lines.
Dr. Bedogni showed that Akt induces Notch1 through
NFkB. Moreover, skin hypoxia contributes to Akt-depen-
dent Notch1 activation through HIF1a. Dr. Bedogni con-
cluded that Notch1 is required by Akt to maintain a
transformed phenotype in the mild hypoxic environment
of the skin, possibly by maintaining melanoma cells in
an undifferentiated state.
Day 2 ⁄ Session 1. What went wrong in the wiring of
melanoma (I): Receptors. Chair: Meenhard Herlyn
Dr. Herlyn (Wistar Institute, Philadelphia, PA) has previ-
ously described culture techniques for the generation of
melanocytes from human embryonic stem cells
(hESCs). This requires growth of hESCs in embryoid
bodies and the addition of growth factors Wnt3a, ET3
and bFGF. In this session he described the isolation of
melanocyte stem cells from hair follicles and dermis,
which have neural stem cell characteristics. When cul-
tured under the appropriate conditions, these cells can
give rise to melanocytes, neuronal or smooth muscle
cells, chondrocytes or adipocytes. Dr. Herlyn has used
these cells in human skin reconstructs to test the
effects of melanoma relevant oncogenes. In addition,
Dr. Herlyn is analyzing bona fide human melanoma
specimens to identify melanoma stem cells. His data
suggest that melanoma specimens are complex in that
they may contain multiple populations of cells with
tumor-initiating capacity. Some of the characteristics of
these cells are: expression of CD20 (often co-expressed
with Mel-CAM) and ⁄ or CD133, PKH67 GFP label reten-
tion (i.e., slow proliferation) and their presence as a
‘‘side population’’ when stained with Hoecsht dyes.
Dr. Herlyn is currently subjecting these cells to various
analyses to understand their characteristics in more
detail and their contribution to melanoma dormancy,
invasion, metastasis and drug resistance.
Mary Hendrix (Northwestern University, Chicago, IL)
described experiments that implicated the secreted
TGF-b superfamily member Nodal as a regulator of the
phenotype of aggressive melanoma cells. Under normal
developmental circumstances Nodal is a stem cell mar-
ker that plays an essential role in mesoderm formation
and axis specification. Nodal secretion by melanoma
cells was identified using a novel assay for embryonic
axis duplication in zebrafish in conjunction with mRNA
analysis using cDNA microarrays. Dr. Hendrix also noted
that Nodal expression was elevated in more aggressive
melanoma cells compared to their less aggressive coun-
terparts. The activity of tumor specific Nodal expression
was promoted by Notch signaling and inhibited by
expression of Lefty, produced by embryonic stem cells.
This effect may be mediated by methylation of the
Nodal promoter. Dr. Hendrix proposed that Nodal
expression might be a marker of poor prognosis. Fur-
thermore, inhibition of Nodal expression in melanoma
cells led to a reduction in VE-cadherin expression,
resumption of melanin biosynthesis and reduced tumor
growth, thereby directly linking Nodal expression to the
aberrant physiology of the melanoma cell.
Maria Soengas (University of Michigan, Ann Arbor,
MI) presented initial data regarding autophagy in mela-
noma. Cell death can occur by necrosis, apoptosis or
through autophagy. Necrosis is not a genetically con-
trolled process, but both apoptosis and autophagy are
controlled by elaborate machinery that appears to share
some common components. However, whereas apopto-
sis is solely dedicated to promoting cell death, auto-
phagy can be a protective response that promotes cell
survival in the face of nutrient deprivation. Dr. Soengas
presented data suggesting that cyclopamine-mediated
inhibition of Sonic hedgehog (SHH) signaling through its
receptor complex, Patched (PTC) and Smoothened
(SMO), leads to activation of a protective autophagy
response. This was surprising since this pathway has
not previously been linked to autophagy. This response
was not dependent on the mutational status of NRAS,
BRAF or TP53. However, when cyclopamine was
administered in conjunction with either mild hypoxia or
serum deprivation, there was extensive cell death.
These data indicate that the SHH fi PTC fi SMO path-
way may be a relevant target for melanoma therapy.
This is a provocative notion since there are a number of
SMO antagonists currently in late-stage preclinical test-
ing or in early clinical trials.
Elena Pasquale (Burnham Institute, La Jolla, CA)
described recent work on Ephrin (Eph) receptors and
their ligands. In vertebrates, there are 10 EphA (A1-A10)
and 6 EphB (B1-B6) receptors. There are also 5 EphA
ligands (Ephrin A1-A5) and 3 EphB (B1-B3) ligands. Eph-
rins and their Eph receptors are implicated in numerous
processes such as axon guidance, cell adhesion and cell
migration during development, homeostasis and dis-
ease. Moreover, Ephrin ligand-receptor interaction can
initiate bi-directional signaling such that both the Ephrin
ligand and the Eph receptor expressing cells initiate sig-
naling events in response to ligand-receptor engage-
ment. Dr. Pasquale described the interaction between
EphA4 and SPAR (Spine associated Rap.GAP). This
interaction occurs through the PDZ domain of SPAR and
leads to decreased Rap.GTP within the cell. Rap
signaling has been implicated in the regulation of cell
adhesion and motility through its effects on the affinity
Meeting Report
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state of integrins. Consequently, Dr. Pasquale claimed
that using an anti-EphA4 Fc fragment leads to a
decrease in active b1-integrin that in turn promotes cell
migration. By contrast, over-expression of an activated
form of Rap1 reverses this phenotype. Finally, Dr. Pas-
quale noted that SPAR is identical to E6TP1, a protein
that binds to the E6 oncoprotein of human papilloma
virus and is subsequently proteolyzed. This observation
potentially links SPAR ⁄ E6TP1 to the pathogenesis of
human cervical cancer. In separate experiments,
Dr. Pasquale described that EphB4 is expressed in a
wide variety of melanomas and that expression corre-
lates with invasion and metastasis. Dr. Pasquale
described the generation of a peptide that competes for
the EphB4 ligand-binding site, and does so at remark-
ably high affinity. Peptide-mediated blockade of the
interaction between EphB4 and its natural ligands may
be an effective strategy to inhibit melanoma cell inva-
sion and metastasis.
Day 2 ⁄ Session 2. What went wrong in the wiring of
melanoma (II): Kinases. Chair: Martin McMahon
Dr. McMahon (UCSF Comprehensive Cancer Center,
San Francisco, CA) opened the session by discussing
the macro and micro effects of the BRafV600E mutation
on the biology of melanocytes. When expressed at low
levels BRafV600E induces cell cycle progression; how-
ever, even at moderate levels it induces growth arrest
by inducing the expression of cell cycle inhibitors
p21Cip1, p16Ink4a and p15Ink4b. Dr. McMahon
reported the generation of mice carrying a Cre-activated
BRafV600E allele. Mating these animals with mice harbor-
ing a 4-hydroxytamoxifen-inducible Cre recombinase-
estrogen receptor fusion transgene under the control of
the tyrosinase promoter resulted in melanocytic hyper-
plasias after tamoxifen treatment. Interestingly, these
pigmented lesions did not show evidence of melanoma
progression unless combined with loss of Pten function,
in which case the lesions progressed rapidly to malig-
nant melanoma with evidence of invasion and distant
metastasis. Marcus Bosenberg (University of Vermont,
Burlington, VT) then continued the discussion of these
genetically engineered mice with a focus on melanoma
progression and metastasis. Animals with an activated
BRafV600E allele on an Ink4a ⁄ Arf-deficient background
rarely displayed melanoma lesions. However, the rare
tumors that did appear showed rapid melanoma pro-
gression. In contrast, when activated BRafV600E was
combined with loss of three tumor suppressor genes:
Pten, Ink4a and Arf, the animals displayed robust forma-
tion of primary cutaneous malignant melanomas with
dramatic evidence of lymph node invasion and evidence
of metastasis to several organs.
Richard Marais (Institute of Cancer Research, London,
UK) described the generation of a mouse model
that was quite similar to the one described by
Drs. McMahon and Bosenberg. However, in this case,
activation of BRafV600E expression during embryogene-
sis led to a multiplicity of developmental defects that
include macroencephaly, surface brain nodules, heart
and eye defects that led to lethality. Cells isolated from
these mice proliferated in tissue culture and generated
tumors as xenografts. Genotyping suggested that the
transformed cells were melanoblasts. Using a conditional
Cre allele generated by Dr. Lionel LaRue, Dr. Marais
described the effects of BRafV600E expression in adult
melanocytes that bore strong similarity to the data of
Drs. McMahon and Bosenberg, with the exception that
Dr. Marais saw evidence of frank melanoma progres-
sion at late times after BRafV600E expression. Finally,
Dr. Marais discussed that BRAFV600E regulates MITF
expression through effects on MEK ⁄ ERK signaling and
the transcription factor BRN2. Moreover, BRAFV600E
acts through MITF to promote expression of compo-
nents of the cell cycle machinery leading to melanoma
cell proliferation.
Frank McCormick (UCSF Comprehensive Cancer Cen-
ter, San Francisco, CA) discussed the success and fail-
ure of therapies targeted to oncogenes. Dr. McCormick
described how drug resistance, activation of critical sig-
naling pathways and tumor heterogeneity affect survival
benefits of such therapies. In particular, it was demon-
strated that single molecule agents are not effective in
treating malignant melanoma. A paradigm of such failure
is the multi-kinase inhibitor Sorafenib, which paradoxi-
cally is active in renal cell and hepatocellular carcinomas.
Once more, melanoma shows its ability to escape from
promising therapies.
Day 2 ⁄ Minisymposia Session A. Immunobiology.
Chair: Soldano Ferrone
Dr. Ferrone (University of Pittsburgh, Pittsburg, PA)
began by first announcing that he was chairing the ses-
sion in place of Dr. Alan Houghton, to whom he wished
a speedy recovery. Dr. Ferrone’s research focus has
been on immunity to the high molecular weight mela-
noma-associated antigen (HMW-MAA). This antigen is
present not only on melanoma cells, but also on glioma,
chordoma, chondrosarcoma and acute lymphoblastic
leukemia. Immunity to this antigen is also thought to
represent a means of angiogenic targeting. Dr. Ferrone
presented data from a prior clinical trial using an anti-
idiotypic monoclonal antibody in patients with mela-
noma. Patients who developed an antibody response to
HMW-MAA as a result of the anti-idiotype antibody had
better overall survival compared with historical controls.
Dr. Ferrone is now using the antibody in a SCID mouse
model using breast cancer cells thought to have stem
cell-lime properties. Evidence for an anti-angiogenic
effect was presented.
Jedd Wolchok (Memorial Sloan-Kettering, New York,
NY) presented data on the use of immunomodulatory
antibodies as therapies for melanoma in both preclinical
and clinical studies. The most advanced approach is the
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use of anti-CTLA-4 monoclonal antibodies, currently in
phase III studies by Medarex ⁄ BMS as well as Pfizer.
There have been documented clinical responses as well
as reversible immune-related adverse events, serving as
proof of principle for the mechanism. Data showing the
spectrum of kinetics of clinical response as well as
induction and augmentation of immune responses to
cancer-testis antigens was also presented. This
approach has significant potential in the therapy of met-
astatic melanoma patients. Preclinical studies of anti-
bodies to GITR and OX40 in the B16 mouse model
have demonstrated significant biologic activity.
Raphael Clynes (Columbia University, New York, NY)
gave an insightful presentation regarding the importance
of Fc receptors in tumor immunity. Dr. Clynes’ prior
work has clearly shown the necessity of Fc receptors in
mediating the anti-tumor effects of rituximab and trast-
uzumab in mouse models. He has also worked exten-
sively using TA99, a monoclonal antibody recognizing
TRP-1, and showed that Fc receptors are required for
the tumor protection and autoimmune hypopigmentation
mediated by TA99 in the B16 model. One hypothesis
for the efficacy of monoclonal antibodies is that they
may allow for cross-presentation of their target antigens
through Fc receptor binding on antigen presenting cells.
This has been evaluated in mice using ovalbumin and
now in human breast cancer patients who had received
trastuzumab in the past. A subset of patients treated
with trastuzumab develops antibodies to her-2 ⁄ neu, and
these patients appear to have a superior clinical out-
come to similarly staged and treated patients who did
not develop antibodies.
Cassian Yee (Fred Hutchinson Cancer Research
Center, Seattle, WA) presented his group’s data on the
use of adoptive transfer of T cell clones in patients with
metastatic melanoma. The approach Dr. Yee is using
involves ex vivo expansion of CD8+ and CD4+ clones
and transfer into patients treated with fludarabine for
lymphodepletion. Serum IL-7 and IL-15 levels increase
approximately one week following fludarabine, suggest-
ing the induction of homeostatic proliferation. The most
recent trial has used CD4+ T cell clones directed to epi-
topes on tyrosinase and NY-ESO-1. Early data show
several clinical responses of this approach.
The final presentation of the session was by Kate
Dadachova (Albert Einstein College of Medicine, Bronx,
NY). Dr. Dadachova has been working with an anti-mela-
nin monoclonal antibody that was originally raised to
fungal melanin (Cryptococcus) but also recognizes mela-
noma cells. A phase I trial has been initiated in Israel
investigating the effects of a radio-labeled form of the
antibody in melanoma patients.
Day 2 ⁄ Minisymposia Session B. Gene
expression ⁄ micro RNA. Chair: Jeffrey Trent
This session chaired by Dr. Trent (Tgen, Phoenix,
Arizona) began with a talk by Dr. Kevin Brown (TGen,
Phoenix Arizona), who discussed the use of mining geno-
mic and phenotypic data to identify novel melanoma
genes. For such studies, they are using a panel of early
passage primary melanomas treated or not with the
chemotherapeutic agent temozolomide. Dr. Aleksandar
Sekulic (TGen, Phoenix, Arizona) discussed the use of
high-resolution oligo-CGH for the detection of subgenic
modifications in melanocytic nevi and melanomas. Inter-
estingly, this group reported that benign nevi already
show small deletions and copy number variations.
Dr. Nick Hayward (Queensland Institute for Medical
Research, Herston, Australia) reported the use of geno-
mic copy number with global mRNA and microRNA for
cataloging genes in melanoma development. Dr. Alain
Spatz (Institut Gustave Roussy, Villejuif, France)
described the identification of gene-profile signatures for
human primary malignant melanoma associated with
metastasis to distant sites and poor prognosis. DNA repli-
cation and DNA repair pathways were among the most
significant pathways associated with progression to
metastasis. The overexpression of DNA repair genes
could mediate the notorious resistance of metastatic
melanoma tumors to current therapeutical modalities.
Dr. Daniel Peeper (The Netherland Cancer Institute,
Amsterdam, The Netherlands) described a study aimed at
defining mediators of BRAFV600E-induced senescence.
Microarray analysis identified Il-6 as a major outlier.
Dr. Peeper also found that C ⁄ EBPb, a downstream target
of Ras signaling, is activated by BRAFV600E. Functional
studies demonstrated that induction of senescence by
Il-6 is cell-autonomous. This group also reported that
C ⁄ EBPb is recruited to the Il-6 promoter, thus these pro-
teins may control sets of overlapping genes in oncogene-
induced senescence. Together, the studies discussed in
this session may lead to the discovery of new prognostic
markers and therapies for the treatment of melanoma.
Day 2 ⁄ Minisymposia Session C. Epidemiology and
prevention of melanoma. Chair: Richard Gallagher
Dr. Gallagher (BC Cancer Research Centre, Vancouver,
Canada) reported that sunbed use is increasing in most
western countries particularly among young people, and
concerns have arisen about their effect on melanoma
risk. Because most studies to date have been small, risk
estimates have been unstable with wide confidence
intervals. Several recent meta-analyses have been
conducted, and show a modest elevated risk for ‘ever’
versus ‘never’ use of sunbeds (RR=1.15; 95% CI= 1.00-
1.31). Control for concomitant sun exposure produces
little change in the point estimate of risk. First exposure
‘in youth’ (earlier than age 35) appears to further
increase risk (RR=1.75; 95% CI=1.35-2.26), and risk
appeared to be higher with exposures ‘distant in time’
by comparison with ‘recent’ exposures. Dr. Gallagher
concluded that findings of increased risk with early life
use, coupled with what appears to be a greater risk
with increased lag time, parallel trends seen with
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exposure to solar UV radiation and suggest that an
appropriate public health policy might be to more
severely restrict use of sunbeds by those under the age
of 18.
David Whiteman (Queensland Institute of Medical
Research, Brisbane, Australia) reviewed the accumulat-
ing evidence from epidemiologic studies that cutaneous
melanomas arise through different causal pathways. In
the realm of descriptive epidemiology, it is now clear
that the patterns of age-specific incidence of melanoma
at different anatomical sites behave in a consistent man-
ner in all fair-skinned populations. Melanomas arising on
intermittently exposed body sites are significantly more
common among younger and middle-aged adults,
whereas melanomas of the head and neck are most
common among older people. Dr. Whiteman reviewed
data from analytical epidemiologic studies that have
generally supported these findings, and have shown
that people who develop melanoma of the head and
neck tend to have fewer nevi, greater lifetime exposure
to sunlight and more evidence of chronic solar damage
than those who develop melanoma of the trunk. Most
recently, molecular epidemiologic studies have explored
this issue by comparing the characteristics of melano-
mas harboring BRAF mutations compared to those with
wild-type BRAF. BRAF mutant melanomas tend to arise
on the trunk and occur among younger people with
many nevi. Dr. Whiteman concluded that taken
together, these epidemiologic findings accord with
recent molecular and animal studies that melanomas
arise through multiple causal pathways.
Nancy Thomas (University of North Carolina, Chapel
Hill, NC) discussed how the Genes, Environment and
Melanoma (GEM) consortium used mutational analysis
of melanoma as a tool for investigating causal pathways
in melanoma. She discussed their results that melano-
mas with BRAF mutations and melanomas with NRAS
mutations were associated with different risk factors.
Compared to patients with neither mutation in their mel-
anoma, patients with BRAF-mutant melanomas tended
to be younger, to have a lot of moles, and to have lived
in a sunny climate between ages 0 and 25. Patients
with NRAS-mutant melanomas also tended to have
increased numbers of moles, but were typically older
and tended to have lived in a sunny climate after age
50. Dr. Thomas concluded that both early and late life
sun exposure are important to risk, albeit for different
tumor genotypes. Thomas also discussed that theories
of melanoma heterogeneity were supported by unique
incidence and age distribution patterns by site of mela-
noma examined using the large Surveillance, Epidemiol-
ogy, and End Results Program (SEER-17) database.
Mark Elwood (BC Cancer Research Centre, Vancou-
ver, Canada) presented a summary of an analysis of
melanoma occurrence in Queensland, Australia, which
has the highest incidence of melanoma in the world. A
unique series of detailed studies in this community
makes it possible to describe the occurrence, diagnosis,
primary management and outcomes for melanoma, as
well as the knowledge, attitudes and screening and pre-
ventive practices of the population. Knowledge about
skin cancer is very high, and high proportions of the
population practice skin self-examination, and ⁄ or have a
regular skin screening from a physician; yet most mela-
nomas are detected as incidental findings. Dr. Elwood
reported that greater awareness and surveillance has
given a great increase in the diagnosis of thin melano-
mas; however, this trend has not been followed by any
clear reduction in the incidence rate of more deeply
invasive melanomas. Dr. Elwood suggested that this
finding has many possible implications, one being how
often thin melanoma is not, biologically, destined to pro-
gress to thicker and metastatic melanoma. This is an
issue that cannot be directly studied in humans and
must be assessed from clinical and epidemiological
data.
Marianne Berwick (University of New Mexico Cancer
Center, Albuquerque, NM) talked about gene-environ-
ment interaction in melanoma, focusing on the popula-
tion-based evaluation of genetic variants in the major
familial melanoma gene, CDKN2A, its prevalence and its
interaction with sun exposure. Dr. Berwick presented
data indicating that 1.2% of 2,424 melanoma patients
from the general population from the US, Canada, Italy
and Australia had a functional mutation in this gene and
that 3.2% of 1,189 patients with multiple primary mela-
nomas from the same population registries in the 4
countries also had a functional mutation in this gene.
Therefore, an almost 5-fold increased risk for developing
melanoma with a CDKN2A mutation was found, lower
than the 10-fold increased risk anticipated based on pre-
vious, family-based studies. In the same study, the
GEM study group found that excessive intermittent sun
exposure over a lifetime increases risk about 1.6-fold,
similar to previously reported meta-analyses. Synergistic
interactions between sun exposure and mutations in
CDKN2A were detected in a ‘‘case-only’’ design,
although not in a case-control study design. Dr. Berwick
finished by asserting that all subjects, not only mutation
carriers, should practice ‘‘safe sun’’ exposure - that is,
avoiding intense intermittent sun exposure during their
lifetime.
Day 2 ⁄ Minisymposia Session D. Clinical updates.
Chair: Lynn Schuchter
The session began with Dr. Schuchter (University of
Pennsylvania, Philadephia, PA), who discussed 2010 as
a target date for improving survival in patients with mel-
anoma. In this session, Dr. Schuchter explored the
unique challenges in melanoma treatment and the cur-
rent obstacles to achieving the 2010 goal. Ongoing
phase III clinical trials were reviewed, and it is not clear
that existing phase III clinical trials are on target to
improve overall survival in patients with metastatic,
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stage IV melanoma. Dr. Schuchter raised a number of
key points during this presentation. When planning for
clinical trials, particularly with targeted agents, it is criti-
cal to recognize the heterogeneity of melanoma with
respect to molecular as well as clinical characteristics.
Clinical trials will need to have sufficient power to take
into account this heterogeneity; therefore much larger
phase II and phase III studies will be needed. Optimally
defined patient populations are key, especially for tar-
geted therapies. There should be mandatory collection
of tumor blocks on all patients enrolled on clinical trials,
a practice that is critical to understanding the relation-
ship between various molecular alterations and
response ⁄ resistance to therapy. Well defined, consis-
tent metrics of success of phase II studies (i.e., PFS)
are needed to appropriately select treatment regimens
for the next phase III studies. It will be critically impor-
tant to coordinate ongoing phase II studies so that we
are poised to test the best agents in the properly
selected patients in phase III studies. Future efforts will
require a highly organized effort across clinical centers
with close collaboration with scientists.
Keith Flaherty (University of Pennsylvania, Philadel-
phia, PA) presented an update on the clinical develop-
ment of RAF and MEK inhibitors. Unregulated
intracellular signaling in the MAP kinase and PI3 kinase
pathways appears to be central to melanomagenesis.
The rationale for targeting MAPK pathway was pre-
sented. Currently there are three drugs in clinical devel-
opment that target BRAF. Sorafenib, the least selective
agent, was the first available RAF kinase inhibitor that
was available in 2002 when BRAF mutations were first
identified in melanoma. Clinical trials with sorafenib,
400 mg given orally twice a day, as a single agent
showed little activity in more than 50 patients with met-
astatic melanoma. However, when combined with che-
motherapy sorafenib appears to have greater clinical
activity, which has led to three randomized clinical trials.
Agents undergoing testing in combination with sorafenib
include dacarbazine, temozolomide, paclitaxel and car-
boplatin. More potent and selective RAF inhibitors (RAF-
265) and PLX4032 are currently being evaluated in
phase I ⁄ II clinical trials. These agents also appear to
have greater selectively against BRAF and NRAS mutant
lines in vitro. In the second part of his presentation,
Dr. Flaherty discussed whether MEK inhibition offered
an advantage over RAF inhibitors. Two MEK inhibitors
are currently being evaluated in patients with mela-
noma, PD 0325901 and AZ26244.
Barry Allen (University of New South Wales, Sydney,
Australia) presented the results of a preliminary study
on the use of alpha-emitting radioisotope Bi-213 che-
lated to the 9.2.27 monoclonal antibody, which is highly
specific for the melanoma-associated chondroitin sulfate
proteoglycan NG2, to form an immunoconjugate. Forty
patients with stage IV melanoma were treated. There
was no evidence of toxicity and responses were seen,
with 12% of patients experiencing regression of subcu-
taneous lesions. The mechanism of the anti-tumor
response is not clear. Dr. Allen suggested that the
responses seen were not related to targeted alpha ther-
apy. Rather, Dr. Allen’s hypothesis is that observed
regression of tumors was mediated by a mechanism
called tumor antivascular therapy (TAVAT). This effect
depends on the vascular permeability of tumor capillar-
ies, the expression of targeted receptors by capillary
pericytes and contiguous melanoma cells, and on the
short range and high-energy transfer of alpha radiation.
Rhoda Alani (Johns Hopkins University School of
Medicine, Baltimore, MD) and her colleagues have
taken a reductionist view of tumor metastasis by evalu-
ating direct interactions between melanoma cells and
endothelial cells in order to better understand cell-cell
communications that take place during metastatic
events. Dr. Alani has identified neuropilin 2 (NRP-2), a
member of the neuropilin family of transmembrane gly-
coproteins, as a gene that is upregulated in melanoma
cells during interactions with endothelial cells. NRP2 is
involved in neuronal cell migration during development
and is implicated in tumorigenesis and angiogenesis
through its involvement in the VEGF signaling pathways.
This group has found that inhibition of NRP-2-related sig-
naling using blocking antibodies has yielded a greater
than 90% reduction in proliferation of melanoma cells.
Random melanoma cell migration and melanoma inva-
sion is also reduced in the presence of NRP-2 blocking
antibodies. Interestingly, siRNA-mediated silencing of
NRP-2 does not significantly impede melanoma cell pro-
liferation, suggesting a novel titration mechanism involv-
ing VEGF and VEGF receptors in vivo. Preclinical studies
already underway in a mouse model system will help
further define the role of NRP-2 in melanoma metasta-
sis in vivo. Since humanized monoclonal antibodies to
NRP-2 are currently under development as anti-angio-
genic therapies, Dr. Alani has proposed that such novel
therapies will be specifically useful as targeted therapies
for melanoma given their anti-tumoral effects in these
cancers, and she expects that phase I clinical trials of
these targeted agents will include significant numbers
of melanoma patients at the outset.
Kowichi Jimbow (Sapporo Medical University School
of Medicine, Sapporo, Japan) and his colleagues
reported on their new approach, melanogenesis-tar-
geted therapy, drug delivery system and chemo-thermo-
immunotherapy. This is based upon their previous work
that showed that the N-propionyl derivative of cysteami-
nylphenol is a good tyrosinase substrate, and is selec-
tively incorporated into melanoma cells. Encouraging
anti-melanoma effects have been seen in patients with
stage III and Stage IV melanoma.
Paul Chapman (Memorial Sloan-Kettering Cancer Cen-
ter, New York, NY) presented very early results from a
phase II study of neoadjuvant temozolomide in patients
with melanoma. The overall goal of this ongoing study
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was to identify tumor characteristics associated with
response to Temozolomide. To be eligible for this study,
patients were required to have palpable disease and be
candidates for complete resection of melanoma. Treat-
ment consisted of a pretreatment tumor biopsy, followed
by extended dosing of Temozolomide at 75 mg ⁄ m2 daily
for 6 weeks followed by 2 weeks off. Patients were trea-
ted until best response and then surgery was performed.
To date, 13 patients have been treated, with 2 complete
responses and 1 partial response. Tumor biopsies are
being evaluated for MGMT promoter methylation. Impor-
tantly, as presented by Dr. Chapman, this neoadjuvant
approach offers a unique opportunity to study tumor
tissue before and after treatment.
Striking at this session was the wide gap between
ongoing basic science of melanoma and clinical trials.
The need for communication between basic scientists
and clinicians has never been more critical.
Day 2 ⁄ Session 3. What went wrong in the wiring of
melanoma (III): Transcription factors. Chair: Colin
Goding
Dr. Goding (Marie Curie Research Institute, Oxted, UK)
highlighted the regulation of the Microphthalmia-associ-
ated transcription factor MITF as a key factor in mela-
noma proliferation and metastasis. Previous work from
this group demonstrated how MITF is necessary to
maintain expression of Dia1, a diaphanous-related formin
that coordinates the actin and microtubule networks at
the cell periphery and indirectly controls the stability of
the p27 cyclin-dependent kinase inhibitor. Thus cells
with low MITF exhibit a p27-dependent G1 arrest and
have high invasive potential. Since MITF is highly regu-
lated at the transcriptional and post-transcriptional levels,
the data suggest a model in which melanomas contain
MITF-positive proliferating ⁄ differentiating cells, and an
invasive MITF-negative population, and that switching
between these two populations would be regulated by
the microenvironment. To identify the MITF-negative
cohort, they first identified the BRAF and b-catenin regu-
lated Brn2 transcription factor as a negative regulator of
the MITF promoter. Then, Dr. Goding showed that areas
of tumors that would normally be classified as double
positive for MITF and Brn2 by conventional immunohis-
tochemistry of adjacent sections, in fact contained two
distinct cohorts as determined using double immunofluo-
rescence. The data support the idea that the success of
any therapy must take into account the heterogeneous
nature of melanoma at the cellular level. Dr. Goding’s
data showing that Brn2 represses MITF expression was
in contrast to those of Dr. Marais, who showed that
Brn2 could activate MITF expression; it was concluded
that Brn2 activity is likely cell line dependent.
Lionel Larue (Institut Curie, Orsay, France) discussed
the function of an oncogenic mutant form of b-catenin
in melanocytes in vivo, as well as the function of its tar-
get Brn2. Importantly, b-catenin was found to induce
melanocyte immortalization by directly repressing
p16INK4a expression, and to cooperate with NRAS to
produce melanoma and metastases. Threonine and ser-
ine residues are highly conserved in the pou domain of
Brn2. In order to understand the function of such resi-
dues, transgenic mice expressing wildtype Brn2 or
mutationally inactivated Brn2 (Brn2AA) were generated
and characterized. Dr. Larue reported that wildtype
Brn2, but not Brn2AA, induced melan-a cell proliferation
in vitro. Brn2 wildtype mice exhibited a slight hyperpig-
mentation of the extremities, while Brn2AA mice
showed a white belly spot and hypopigmented tail and
paws. Brn2AA was found to be dominant over wildtype
Brn2. Interestingly, both Brn2AA and wildtype Brn2
were able to repress the expression of MITF. However,
Brn2 activated Pax3 expression while Brn2AA repressed
Pax3 expression. Notably, transgenic mice expressing
either wild-type Brn2 or the Brn2AA mutant failed to
develop melanoma.
Gerard Evan (UCSF Comprehensive Cancer Center,
San Francisco, CA) reviewed the prospects for exploit-
ing the potential of the transcription factors Myc and
p53 as therapeutic targets. Using an experimental
approach he calls ‘‘kinetic genetics’’, Dr. Evan can acti-
vate estrogen receptor (ER) fusions of these transcrip-
tion factors in vivo by exposing appropriately genetically
engineered mice to tamoxifen. This effect is reversible,
as withdrawal of tamoxifen inhibits the fusion protein.
For example, Dr. Evan showed that re-expression of
p53 was lethal to p53 deficient tumors, which suc-
cumbed to massive apoptosis. Tetracycline inducible
expression of OmoMyc, a potent dominant negative leu-
cine zipper able to poison partner interactions, also erad-
icated tumor tissue, even in mouse cancer models not
driven by Myc. Surprisingly, these Myc impaired mice
were relatively healthy, a positive sign when thinking
about possible clinical value. When considering p53 and
Myc as therapeutic targets, Dr. Evan stressed that it will
be important to determine if these tumors recur after
‘‘treatment’’, and if so will they then respond to a
second round.
Gianluca Civenni (University of Zurich, Zurich, Switzer-
land) presented evidence that metastatic human mela-
nomas and melanoma cell lines contain a cellular
subpopulation resembling neural crest stem cells (i.e.,
p75+). These p75+ cells were reported to be able to
form tumor spheres, and self-renew and form tumors
upon serial transplantation resembling the tumor of ori-
gin, while their p75- counterpart cannot. The melanoma
stem cell is an extremely exciting concept, but more
data will be needed to prove its existence and the value
its treatment may bring to the clinic.
Therese Becker (Westmead Institute for Cancer
Research, Sydney, Australia) described her use of a
yeast-two-hybrid screen to identify the chromatin-
remodeling factor BRG1 as a novel p16INK4a binding
partner. Becker found that the endogenous proteins
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interact in melanoma cells and normal dermal human
fibroblasts. Over-expression of p16INK4a, BRG1 or both
proteins combined revealed that p16INK4a alone caused
limited arrest in cells expressing pRb but lacking BRG1.
Co-expression of BRG1 with p16INK4a led to complete
cell cycle arrest in these cells while BRG1 alone did not
affect the cell cycle. Becker’s data demonstrate that
pRb does not strictly require BRG1 to inhibit prolifera-
tion in response to p16INK4a, as was suggested previ-
ously. Furthermore, these data show that BRG1 is able
to amplify p16INK4a-induced growth arrest through
BRG1-INK4a interactions. Becker concluded that BRG1
may be a potentially important tumor suppressor in mel-
anoma, and in fact BRG1 expression is frequently lost in
thick primary melanomas.
Day 3 ⁄ Session 1. Where are we headed (I):
Promising models and pathways. Chair: Lynda Chin
Dr. Chin (Dana Farber Cancer Institute, Boston, MA)
opened the session by discussing how integrative
genomics such as array-based comparative genome
hybridization (array-CGH) has been used to identify
novel melanoma oncogenes such as NEDD9. Potential
uses for these technologies are the identification of real
tumor drivers from genomic bystanders, functional
genetic screens for the identification of pre-existing
genes in thin versus thick primary melanomas, and
genes present in thin melanomas that predispose to
metastatic disease.
Glenn Merlino (National Cancer Institute, Bethesda,
MD) discussed work that was focused on the earliest
initiating stages of melanoma. He presented a new
mouse model that can be used to determine the molec-
ular consequences to melanocytes of exposure to UV
radiation in vivo. In this bitransgenic model, the dopa-
chrome tautomerase (DCT) gene promoter is used to
drive melanocyte-specific, doxycycline-inducible expres-
sion of GFP. This in vivo model is attempting to provide
novel insights into the nature of UV-induced ‘‘damage,’’
and the mechanisms by which UV provokes melanoma.
In addition, using a series of animal- and cell culture-
based models of melanoma, Dr. Merlino reported that
oncogene-induced senescence, a barrier against early
tumor progression, can be overcome by a deficiency in
the tumor suppressor ARF, but not p53, facilitating rapid
development of melanoma. Accordingly, oncogenic
NRAS was found to collaborate with a deficiency in
ARF, but not p53, to fully transform melanocytes in vitro.
This data may help explain in human melanoma the rela-
tive abundance and paucity of mutations in ARF and
TP53, respectively, and demonstrate that ARF and p53
suppress tumorigenesis through diverse, lineage-depen-
dent mechanisms.
Murray Robinson (Aveo Pharmaceuticals, Cambridge,
MA) described the generation of chimeric, embryonic
stem cell-based, complex inducible tumor models that
can be used for analyzing the variability of human
tumors to drug-induced tumor regression. Specifically,
Dr. Robinson detailed how this technology has been
used to establish over 100 breast tumors from Her2
overexpressing mice in a null p16INK4a background.
Lewis Cantley (Harvard Medical School, Boston, MA)
discussed the role of the phosphoinositide 3-kinase
(PI3K) signaling pathway in human cancers. The PI3K
enzyme generates PIP3, which in turn controls changes
in signaling networks that regulate proliferation and sur-
vival. Dr. Cantley also discussed how these networks
are modulated by the LKB1 tumor suppressor and
upstream activator, or by AMPK, a key sensor of the
cell’s energy status. LKB1 also negatively regulates
mTOR signaling, a pathway activated in a variety of
human cancers. Current studies show that increased
phospho ERK negatively correlates with phospho AMPK
in human melanoma tissues. Future studies should
determine whether activators of the AMPK pathway
have any benefits for melanoma survival.
Day 3 ⁄ Session 2. Where are we headed (II): Evolving
therapies. Chair: Frank Haluska
The final session, chaired by Dr. Frank Haluska (Tufts-
New England Medical Center, Boston, MA), focused on
therapeutic strategies for melanoma, primarily from the
drug discovery perspective. Dr. Haluska began by
reviewing progress in the discovery of oncogenic muta-
tions in melanoma. He pointed out features of clinical
trial design that are important for rapid and decisive
evaluation of the exciting pipeline of new agents. Nota-
ble clinical caveats were also emphasized, such as the
important, yet infrequently highlighted, differences
between stage 4 disease involving subcutaneous soft
tissues (relatively good prognosis) as compared to vis-
ceral metastases (relatively poor prognosis). Recognition
of such patient characteristics may be crucial for an
ability to draw general conclusions from smaller initial
clinical trial results.
Two different kinase development companies pre-
sented data on the development of small molecules that
target mutated oncogenes. Dr. Joyce James (Ambit Bio-
sciences, San Diego, CA) described a kinome-like library
of kinases that are screened against small molecule
libraries to rapidly define panels of kinase selectivity. A
BRAF inhibitor nanomolar range activity was presented,
together with data describing its biological activity rela-
tive to other BRAF-targeted agents. Dr. Dan Lynch
(Deciphera Pharmaceuticals, Lawrence, KA) provided a
review of different classes of kinase inhibitors, based
upon differing mechanisms of action (e.g., ATP binding
pocket competitive antagonists, allosteric inhibitors,
etc.). He described the BRAFV600E mutant allele as
involving a mutation that is located within a conforma-
tional switching pocket, which has been targeted in
their drug discovery program. They too have developed
a nanomolar BRAF-targeted kinase inhibitor and preclini-
cal data on efficacy were presented.
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Dr. Eric Jacobson (Synta Pharmaceuticals, Lexington,
MA) presented data on the drug STA-4783, a small mol-
ecule that induces oxidative stress. This agent com-
pleted Phase II study for stage IV melanoma in
combination with paclitaxel and demonstrated a statisti-
cally significant increase in progression free survival
(3.7 months vs. 1.8 months). The drug is thought to
induce production of reactive oxygen species and
thereby sensitize cells to apoptotic cell death. Other
mechanistic features, including involvement of heat
shock response factors were also discussed. Currently
a randomized phase III study of this agent in chemother-
apy naı̈ve patients in underway. Dr. Dana Aftab (Exelixis,
South San Francisco, CA) described a recently devel-
oped inhibitor of the KIT kinase. KIT is a receptor tyrosi-
nase kinase that undergoes activating mutations in
gastrointestinal stromal tumors and also a small (though
significant) subset of melanomas. Two FDA approved
small molecule KIT inhibitors have demonstrated signifi-
cant efficacy against KIT mutated GI stromal tumors,
although a set of resistance conferring mutations has
been identified. The Exelixis agent, XL820, was pre-
sented and suggested to retain activity for multiple
mutations within KIT, including several that confer resis-
tance to several other KIT targeted agents.
Looking Ahead
The day after the exciting 4th International Congress of
the SMR adjourned, attendees surely awoke realizing
that melanoma remains an inexplicably lethal disease,
highly metastatic and predictably resistant to currently
available therapeutic modalities. However, if the results
of this meeting are any indication, there is much to be
positive about and many developments upon which to
build for the future. For example, as technological
advances in genomics come into sharper focus, a reli-
able translation is being forged between melanoma
genotype and phenotype. The concept of the melanoma
stem cell is gaining traction, and may hold the keys to
melanoma dormancy, metastasis and drug resistance.
Mouse models of various types of melanoma are
becoming more sophisticated and more relevant, provid-
ing novel mechanistic insights and serving as platforms
for preclinical studies. And the promise of BRAF is now
perhaps beginning to be realized.
From the clinical perspective, this meeting demon-
strated that the technologies required to produce selec-
tive and biologically active targeted small molecules are
alive and well in the pharmaceutical industry. Moreover,
an active pipeline of agents with great pertinence to
melanoma currently exists, and is particularly attractive
because of mechanism-based correlative studies, which
are likely to inform both patient selection and efficacy
variables in future clinical studies. The presence of vig-
orous intermingling among melanoma basic scientists
and drug development experts at the 4th International
Congress of the SMR produced a buzz of excitement
over anticipated progress in the near future.
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